Exclusive Summary

• Lenvatinib is a globally recognized, guideline-recommended 1st-line standard of care for advanced liver cancer and is included in the WHO Essential Medicines List, representing massive clinical demand.
• With the innovator's core patents already expired or non-existent in many emerging markets, now is the absolute prime window to secure distribution rights and capture national tenders in ASEAN, LATAM, and MENA regions.
• Addressing over 1.9 million new annual cases of liver, thyroid, and renal cancers globally, the generic product offers a disruptive cost advantage over the highly expensive innovator drug, rapidly unlocking both out-of-pocket and public procurement sectors.
• Supported by advanced high-containment oncology manufacturing capabilities and ready-to-file eCTD dossiers, seamlessly empowering overseas distributors to achieve rapid, low-risk local regulatory approval and commercialization.